2025.11. 25 本文字数：1901，阅读时长大约3分钟 作者 | 第一财经 钱童心 如今，社交媒体已成为年轻医美消费者的主要信息来源。在小红书上，近期众多医美博主纷纷科普一 种名为羟基磷灰石（CaHA，也称"羟基磷酸钙"）的再生类注射材料。这种材料堪称面部的"骨性生 物支架"，是一种生物刺激剂，能够激发人体组织自身合成新的胶原蛋白，由于这种材料支撑性极 强，也被称作"最硬玻尿酸"。 根据Pharmocean的统计数据，在全球皮肤填充剂市场中，玻尿酸目前占据高达77%的市场份额， 而羟基磷灰石以7%的占比位居第二。 并非所有产品都适用于面部注射 在全球市场上，德国麦施美学（Merz Aesthetics）的芮得怡（Radiesse）是目前唯一一款获得美 国FDA批准的羟基磷灰石面部填充剂产品，并于今年3月获得中国药监机构批准，近日已正式在国内 上市。在国内上市公司中，昊海生科、华熙生物、巨子生物等都在积极布局羟基磷灰石产品，市场竞 争日趋激烈。 然而，这种新兴产品价格高昂，动辄上万元一支的价格也使其成为一些医美机构违规获取暴利的对 象。近期，市场上出现了消费者投诉，称在医疗美容诊所花费数万元注射的产品并 ...

如今，社交媒体已成为年轻医美消费者的主要信息来源。在小红书上，近期众多医美博主纷纷科普一种 名为羟基磷灰石（CaHA，也称"羟基磷酸钙"）的再生类注射材料。这种材料堪称面部的"骨性生物支 架"，是一种生物刺激剂，能够激发人体组织自身合成新的胶原蛋白，由于这种材料支撑性极强，也被 称作"最硬玻尿酸"。 根据Pharmocean的统计数据，在全球皮肤填充剂市场中，玻尿酸目前占据高达77%的市场份额，而羟基 磷灰石以7%的占比位居第二。 并非所有产品都适用于面部注射 在全球市场上，德国麦施美学（Merz Aesthetics）的芮得怡（Radiesse）是目前唯一一款获得美国FDA 批准的羟基磷灰石面部填充剂产品，并于今年3月获得中国药监机构批准，近日已正式在国内上市。在 国内上市公司中，昊海生科、华熙生物、巨子生物等都在积极布局羟基磷灰石产品，市场竞争日趋激 烈。 然而，这种新兴产品价格高昂，动辄上万元一支的价格也使其成为一些医美机构违规获取暴利的对象。 近期，市场上出现了消费者投诉，称在医疗美容诊所花费数万元注射的产品并不具备相关资质，这引发 了关于羟基磷灰石类医美产品超适应症使用的讨论。 第一财经记者查询公开 ...

根据Pharmocean的统计数据，在全球皮肤填充剂市场中，玻尿酸目前占据高达77%的市场份额，而羟基 磷灰石以7%的占比位居第二。 并非所有产品都适用于面部注射 在全球市场上，德国麦施美学（Merz Aesthetics）的芮得怡（Radiesse）是目前唯一一款获得美国FDA 批准的羟基磷灰石面部填充剂产品，并于今年3月获得中国药监机构批准，近日已正式在国内上市。在 国内上市公司中，昊海生科、华熙生物、巨子生物等都在积极布局羟基磷灰石产品，市场竞争日趋激 烈。 然而，这种新兴产品价格高昂，动辄上万元一支的价格也使其成为一些医美机构违规获取暴利的对象。 近期，市场上出现了消费者投诉，称在医疗美容诊所花费数万元注射的产品并不具备相关资质，这引发 了关于羟基磷灰石类医美产品超适应症使用的讨论。 第一财经记者查询公开信息发现，目前国内获批的相关羟基磷灰石填充剂中，明确适应症为面部注射的 仅有两款：除了麦施美学的芮得怡外，另一款为上海摩漾生物的优法兰（Aphranel）。这两款产品的适 应症均为用于鼻唇沟部位皮下注射，以纠正中重度鼻唇沟皱纹。其他几款国产获批产品的适应症则均为 非承重性骨缺损的填充或修复。 近期，市 ...

Core Viewpoint - The article discusses the rising trend of cosmetic surgery among younger generations in China, highlighting the psychological release it provides rather than a complete transformation of self [3][43]. Industry Overview - The Chinese medical beauty market is projected to reach a scale of 350 to 400 billion yuan by 2025, with Generation Z (born after 1995) contributing 62% of the consumption share, averaging an annual expenditure of 28,000 yuan, significantly higher than the "post-80s" generation [9][10]. - The demand for medical beauty services is rapidly increasing, leading to the growth of companies like Huaxi Biological, Aimeike, and Haohai Biological, which are referred to as the "three swordsmen of medical beauty" due to their high profit margins comparable to that of Moutai [10]. Consumer Behavior - Young consumers are increasingly seeking cosmetic procedures as a means of personal expression and self-improvement, often driven by social media influences and peer comparisons [17][39]. - The trend has shifted from invasive surgeries to "light medical beauty," where non-surgical procedures are preferred, reflecting a desire for natural and comfortable appearances [26][30]. Psychological Aspects - The article emphasizes that many young individuals view cosmetic surgery as a solution to their insecurities, often influenced by societal standards of beauty propagated through social media [39][41]. - The experiences of individuals like Chuyu and Yezi illustrate that cosmetic surgery can lead to a psychological release, allowing them to accept themselves better and reduce self-criticism [43]. Market Trends - There is a notable trend of younger individuals, particularly high school and university graduates, seeking cosmetic enhancements as part of their transition into adulthood, often viewing it as a necessary step for confidence in job hunting and social interactions [24][25]. - The article also highlights the increasing prevalence of non-surgical procedures, which are perceived as less risky and more accessible, contributing to the growing popularity of the medical beauty industry among the youth [26][29].

Core Viewpoint - The article discusses the rising trend of cosmetic surgery among the younger generation in China, particularly focusing on the motivations and psychological impacts of such decisions. Group 1: Market Overview - The Chinese medical beauty market is projected to reach a scale of 350 billion to 400 billion yuan by 2025, with Generation Z (born after 1995) contributing 62% of the consumption share and an average annual expenditure of 28,000 yuan, significantly higher than the "post-80s" generation [4]. - The demand for medical beauty services is rapidly increasing, leading to the growth of companies like Huaxi Biological, Aimeike, and Haohai Biological, which are referred to as the "three swordsmen of medical beauty" due to their high profit margins comparable to that of Moutai [6]. Group 2: Changing Attitudes Towards Beauty - The younger generation's perception of beauty is being reshaped by social media, where they are exposed to idealized images that create a sense of inadequacy regarding their own appearances [9][23]. - The concept of "light medical beauty" is becoming mainstream, with a shift from invasive surgeries to less risky procedures like injections, reflecting a desire for a more natural appearance [15][16]. Group 3: Psychological Aspects - Many young individuals view cosmetic surgery as a means to alleviate personal insecurities rather than a drastic change, indicating a psychological release from long-standing self-criticism [24][25]. - The article highlights that the desire for cosmetic enhancements often stems from external societal pressures rather than internal dissatisfaction, leading to a cycle of anxiety about meeting beauty standards [22][23]. Group 4: Personal Experiences - The experiences of individuals like Chuyu and Yezi illustrate the personal motivations behind cosmetic surgery, where the surgery serves as a rite of passage and a way to boost self-confidence as they transition into adulthood [18][20]. - Both individuals report a change in their self-perception post-surgery, feeling more comfortable and confident in their appearances, which reflects a broader trend among their peers [20][24].

Core Viewpoint - The article discusses the rising trend of cosmetic surgery among young people in China, particularly focusing on the motivations and psychological impacts behind their decisions to undergo procedures like double eyelid surgery. It highlights how social media influences perceptions of beauty and self-worth, leading to increased demand for cosmetic enhancements among the younger generation [7][50][54]. Group 1: Market Overview - The Chinese medical beauty market is projected to reach a scale of 350 to 400 billion yuan by 2025, with Generation Z (born after 1995) contributing 62% of the consumption share, averaging an annual expenditure of 28,000 yuan, significantly higher than the "post-80s" generation [7][9]. - The demand for medical beauty services is rapidly increasing, leading to the emergence of companies like Huaxi Biological, Aimeike, and Haohai Biological, which are referred to as the "three swordsmen of medical beauty" due to their high profit margins and market presence [9][29]. Group 2: Changing Attitudes Towards Cosmetic Surgery - There is a noticeable shift in attitudes towards cosmetic surgery, with younger individuals increasingly seeking "light medical beauty" options rather than invasive surgeries. This trend reflects a desire for natural-looking enhancements rather than dramatic changes [27][29]. - The acceptance of cosmetic procedures has evolved, with many young people now viewing them as routine, akin to dental corrections, and not requiring justification for their choices [49][54]. Group 3: Psychological Factors - The article emphasizes that many young individuals experience a form of psychological anxiety regarding their appearance, often exacerbated by social media portrayals of beauty standards. This anxiety can lead to a desire for cosmetic procedures as a means of self-improvement [50][53]. - The narrative illustrates that for some individuals, cosmetic surgery serves as a way to alleviate long-standing self-criticism and to embrace their current selves, rather than a complete transformation [54].

Core Viewpoint - The article discusses the emerging competition and regulatory challenges in the calcium hydroxyapatite (CaHA) market within the medical aesthetics industry, highlighting the recent approvals of CaHA products for facial use and the ongoing issues related to compliance and safety [5][7][11]. Group 1: Market Dynamics - CaHA, originally used in orthopedics and dentistry, is gaining popularity as a facial filler material, alongside PLLA and PCL, driven by market education efforts [3][5]. - In January 2024, it was estimated that the domestic market could consume tens of thousands of CaHA injections, potentially reaching 500,000 units annually, despite a lack of fully compliant products [5][11]. - The approval of two CaHA products for facial use in 2025 marks a significant shift towards regulatory compliance in the industry [5][7]. Group 2: Regulatory Landscape - The first approved CaHA product for facial use, Aphranal® by Moyang Biotechnology, received certification in February 2025, followed by Merz North America's Radiesse, which is the first imported CaHA product approved in China [7][11]. - The competition in the CaHA market is intensifying, with a notable reduction in the time required to obtain regulatory approval, leading to a more crowded market [8][9]. - There are concerns regarding the use of CaHA products beyond their approved indications, with many practitioners using them for facial applications despite their original intended uses being for non-weight-bearing bone defects [13][15]. Group 3: Industry Challenges - The medical aesthetics industry faces significant challenges related to the misuse of products beyond their approved indications, which is prevalent across various injectable products [15][16]. - There is currently no clear legal framework in China to regulate the off-label use of medical devices, leading to potential risks for both practitioners and patients [15][16]. - The article emphasizes the importance of proper patient consent and documentation to mitigate compliance risks in the absence of stringent regulations [16][17].

近年来，新型医美填充材料倍受市场关注。2025年初，琼脂糖、羟基磷灰石相关产品在 国内获批上市，引发了行业对于其技术特点、临床应用、安全性及未来趋势的广泛讨 论。 本次交流会将聚焦这两类材料的特性及应用，为医美行业从业者、投资人、临床医生及 学者提供一个开放讨论的平台，探讨其技术原理、适用场景、操作经验及发展趋势，并 邀请行业专家共同交流。 会议安排 时间： 2025年3月12日（周三）14:30-16:00 地点： 上海交通大学医学院 会议议程 1.介绍八大处整形医学验证中心服务介绍和年度活动计划。 2.主题分享：琼脂糖与羟基磷灰石的技术综述 分享人：思宇MedTech主编赵清 内容概览： #琼脂糖的技术特点 主要成分、凝胶特性及降解机制 与现有填充材料的对比（吸水性、塑形力、适用部位） 近期行业动态及市场趋势 #羟基磷灰石的技术特点 主要成分、刺激胶原增生的作用机制 适用于面部填充的优势与挑战 规模： 20~30人 对象： 医美行业从业者、投资人、临床医生、学者 医美行业对该成分的监管趋势 注：主题分享来自于文献资料的收集。欢迎相关企业代表参与讨论并分享更多观点。 3. 圆桌讨论 & 观点碰撞 琼脂糖 v ...

近年来，新型医美填充材料倍受市场关注。2025年初，琼脂糖、羟基磷灰石相关产品在 国内获批上市，引发了行业对于其技术特点、临床应用、安全性及未来趋势的广泛讨 论。 本次交流会将聚焦这两类材料的特性及应用，为医美行业从业者、投资人、临床医生及 学者提供一个开放讨论的平台，探讨其技术原理、适用场景、操作经验及发展趋势，并 邀请行业专家共同交流。 1.介绍八大处整形医学验证中心服务介绍和年度活动计划。 2.主题分享：琼脂糖与羟基磷灰石的技术综述 分享人：思宇MedTech主编赵清 内容概览： #琼脂糖的技术特点 主要成分、凝胶特性及降解机制 与现有填充材料的对比（吸水性、塑形力、适用部位） 会议安排 时间： 2025年3月12日（周三）14:30-16:00 地点： 上海交通大学医学院 会议议程 注：主题分享来自于文献资料的收集。欢迎相关企业代表参与讨论并分享更多观点。 3. 圆桌讨论 & 观点碰撞 琼脂糖 vs 透明质酸：临床应用上的优劣对比 羟基磷灰石的优势：刺激胶原增生是否带来长期效果？ 两种材料的适用人群及部位探讨 医生的使用体验：注射技巧、并发症管理、患者反馈 市场趋势与投资机会：新材料是否会占据更多市场 ...